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metformin, but also there are reports indicating that 
its adverse effects are negligible when its benefits 
are brought into account.[3] Theoretically, its use has 
been prohibited in a large group of patients with type 
2 diabetes mellitus due to the risk of lactic acidosis. 
However, it has been shown that several diabetic 
patients who are considered to be at risk have received 
metformin with no increased risk of lactic acidosis.[2-5] 
Furthermore, recently some papers have been published 
indicating renoprotective properties for metformin. We 
aimed here to review the new implications of metformin 
and discuss about the concerns in the use of metformin, 
referring to the recently published papers.
NEW AND OLD IMPLICATIONS AND THE 
MECHANISMS OF ACTION
Diabetes mellitus
Metformin is primarily used for the treatment of type 
2 diabetes mellitus, particularly in obese.patients. 
Metformin has been shown to reduce diabetes mortality 
and complications by thirty percent compared to insulin, 
glibenclamide and chlorpropamide.[5]
Metformin reduces serum glucose level by several 
diﬀ erent mechanisms, notably through nonpancreatic 
mechanisms without increasing insulin secretion. 
It increases the eﬀ ects of insulin; hence, it is termed 
“insulin sensitizer”. Metformin also suppresses the 
endogenous glucose production by the liver, which is 
INTRODUCTION
Diabetes mellitus is a group of metabolic disorders in 
which the blood glucose is higher than normal levels, due 
to insuﬃ  ciency of insulin release or improper response 
of cells to insulin, resulting in high blood pressure. 
The resultant hyperglycemia produces the classical 
symptoms of polyuria, polydipsia and polyphagia. It 
may also cause nerve problems, kidney problems, and 
blindness, loss of limbs, and sexual dysfunction, increase 
in heart aĴ ack or stroke.[1] Metformin (a biguanide 
derivative), by controlling blood glucose level decreases 
these complications. Metformin works by helping to 
restore the body’s response to insulin. It decreases the 
amount of blood sugar that the liver produces and that 
the intestines or stomach absorb.[2] Metformin, other 
than hypoglycemic activity, has been taken with diet 
and exercise changes to prevent diabetes in people who 
are at high risk for becoming diabetic. It is also used in 
women with polycystic ovarian syndrome. Metformin 
may make menstrual cycles more regular and increase 
fertility.[3] Metformin was fi rst synthesized and found to 
decrease the blood glucose level in the 1920s; however, 
it was not used for a long time. The use of metformin 
was rekindled in 1957, when the results of a clinical 
trial were published confi rming its eﬀ ect on diabetes. 
Metformin is now widely prescribed as an anti-diabetic 
drug; however, there have been serious concerns about 
its adverse eﬀ ects, especially ketoacidosis.[4] Recently, 
not only some implications have been discovered for 
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mainly due to a reduction in the rate of gluconeogenesis 
and a small eﬀ ect on glycogenolysis. Moreover, metformin 
activates the enzyme adenosine monophosphate kinase 
(AMPK) resulting in the inhibition of key enzymes involved 
in gluconeogenesis and glycogen synthesis in the liver 
while stimulating insulin signaling and glucose transport in 
muscles. AMPK regulates the cellular and organ metabolism 
and any decrease in hepatic energy, leads to the activation of 
AMPK. This study to an extent has put forth to explain the 
mechanism of metformin action on liver gluconeogenesis.[6,7]
Furthermore, metformin increases the peripheral glucose 
disposal that arises largely through increased non-oxidative 
glucose disposal into skeletal muscle. It usually does not 
cause hypoglycemia and this cause to be considered as a 
unique anti-diabetic drug.[8]
Treatment of diabetes with metformin is associated with 
less weight gain compared with insulin and sulfonylureas. 
Weight gain helps in beĴ er glucose control. In a study it was 
shown that, over a 10-year treatment period, the patients 
treated with metformin gained about one kg, the patients 
treated with glibenclamide gained about three kg, and the 
patients treated with the insulin gained six kg weight.[9]
Pre-diabetes
The chance of developing type 2 diabetes mellitus may 
decrease in people at risk for this disease; however, dieting 
and intensive physical exercise may work signifi cantly 
beĴ er for this purpose. In a large study in the United States, 
participants were given placebo, lifestyle intervention 
or metformin, and followed for three years. The lifestyle 
modifi cations included a 16-lesson training on exercise and 
dieting followed by monthly sessions for individuals with 
the aim of decreasing the body weight by 7%. These patients 
under this group were engaged in a physical activity for 
about 150 minutes/week. The incidence of diabetes mellitus 
in this group was by 58%, and in metformin group by 31%. 
AĞ er ten years, the incidence of the disease was lower by 
34% in the patients on diet and exercise and 18% in the 
metformin group.[10]
Gestational diabetes
Several trials have suggested that metformin is as safe 
and eﬀ ective as insulin for the treatment of gestational 
diabetes,[11] and it has been suggested that the mothers who 
have used metformin instead of insulin might be healthier 
in the neonatal period.[12] However, evidence is still lacking 
on the long term safety of metformin for both children and 
mothers.[13]
Polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is frequently associated 
with resistance to insulin and since 1994, metformin 
has been proposed as a treatment for PCOS.[14] In 2004, 
National Institute for Health and Clinical Excellence 
recommended to prescribe metformin for women with 
PCOS and a body mass index above 25 for anovulation 
and infertility when other therapies have failed to produce 
acceptable results.[15] However, several subsequent reviews 
did not show promising results and did not recommend 
it further or at least as a fi rst-line medication,[16] except 
for women with glucose intolerance.[17] The guidelines 
usually suggest clomiphene to be the fi rst treatment and 
recommend lifestyle modifi cation independent from drug 
therapy.
A systematic review using comparative trials of clomiphene 
and metformin found equal results for infertility[18] and A 
BMJ editorial suggested that metformin should be used as a 
second choice, if clomiphene treatment fails.[19] Furthermore, 
a large review using 27 clinical trials found that metformin 
was not associated with any increase in the number of live 
births; however, it improved ovulation rates, especially 
when it was used in combination with clomiphene.[20]
Further, a review recommended metformin as a fi rst choice 
because of positive eﬀ ects on insulin resistance, hirsutism, 
anovulation and obesity, which are oĞ en associated with 
polycystic ovary syndrome.[21]
The diﬀ erent trial designs might be the reasons for the 
contradictory results. For example, considering live birth 
rate instead of pregnancy as the endpoint might have biased 
a few trials against metformin.[22] Another explanation is 
that metformin may have diﬀ erent eﬃ  cacy in diﬀ erent 
populations.
Cancer protection
A large case-control study has suggested that metformin 
might protect patients against pancreatic cancer. In this 
study, the risk of pancreatic cancer in metformin group 
was 62% lower than in placebo group who did not use 
metformin. The participants having sulfonylureas or insulin 
were found to have a 2.5-fold and 5-fold higher risk of 
pancreatic cancer, respectively, in comparison to placebo 
group.[23] Several studies have suggested that diabetic 
patients using metformin might lower the risk of cancer 
compared to those using other anti-diabetic drugs.[24,25] 
However, the results need confirmation in controlled 
trials.[26]
Metformin has shown a strong antiproliferative eﬀ ects 
on colon, pancreatic, breast, ovarian, prostate and lung 
cancer cells. Preclinical studies have also shown reliable 
anti-tumoral eﬀ ects in diﬀ erent animal models. A clinical 
trial has demonstrated benefi cial eﬀ ect in colon and breast 
cancers.[27]
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The mechanism of this action is not clear. Other anti-diabetic 
drugs have not shown the same anticancer activities; hence, 
the anticancer eﬀ ect of metformin should not be related to anti-
diabetic activity of this drug. Metformin possesses antioxidant 
activity.[28] Antioxidants have been shown to have various 
benefi cial eﬀ ects such as anticancer,[29-32] antidiabetes[33] and 
antiatherosclerosis[34,35] properties. Therefore, some benefi cial 
eﬀ ects of metformin might be related to its antioxidant activity.
HIV-associated diabetes
The use of some of antiretroviral drugs in HIV-infection has 
been associated with glucose tolerance, insulin resistance, 
hyperinsulinemia and type 2 diabetes mellitus. Low HDL, 
Hypertriglyceridemia and high risk of cardiovascular 
diseases have been reported in these patients. These 
metabolic alterations are frequently associated with loss of 
subcutaneous fat and increased visceral fat.[36,37]
Antiretroviral therapies with protease inhibitors inhibit 
glucose transporter (GLUT)-4 mediated glucose transport.[38] 
They are likely to be, in part, responsible for the insulin 
resistance and body composition changes in HIV-infected 
patients. Metformin has been shown to reduce visceral 
adiposity and insulin resistance aĞ er 8 weeks of drug 
therapy at dose of 850 mg, 3 times per day.[39]
Nephrotoxicity prevention
Recent studies have suggested that metformin may have 
therapeutic or renoprotective eﬀ ects against nephrotoxic 
agents.[40,41] It has also been shown to have a good eﬃ  cacy 
in diabetic nephropathy.[40-44] Furthermore, it signifi cantly 
decreases albuminuria in patients with diabetes mellitus.[41-44] 
However, the exact mechanism beyond these eﬀ ects is still 
unknown. Recent studies have shown that therapeutic eﬀ ect 
of metformin is mediated through its action on adenosine 
monophosphate (AMP)-activated kinase in tissues.[43-48] 
Various studies have shown that metformin is capable of 
decreasing intracellular reactive oxygen species (ROS).[45-49] 
It protects tubular injury through regulation of oxidative 
stress and restoring the biochemical alterations on renal 
tubules. Metformin may also protect the podocytes in 
diabetic nephropathy.[47-51]
Various studies have shown that AMPK activation of 
metformin is secondary to its eﬀ ect on the mitochondria as 
the primary target.[52] Recent studies have demonstrated a 
direct or mediated mitochondrial eﬀ ect for metformin.[53] 
When metformin is used alone, its benefi cial eﬀ ect is due 
to the mild inhibition of the mitochondrial respiration.[54,55]
The eﬀ ect of mitochondria in programmed cell death is 
usually associated with the release of apoptotic signaling 
molecules.[56] Moreover, ROS production by mitochondria 
may also lead to cell degradation.[57]
Mitochondria represents as one of the major cellular 
sources of ROS generation,[50] and a great number of tissue 
pathologies, which induce oxidative stress.[58,59] These 
fi ndings may show the critical role of mitochondria in these 
conditions.[58,59]
The nephrotoxicity of aminoglycosides and most of other 
renotoxic agents has been aĴ ributed to ROS.[60] In certain 
conditions, intracellular ROS may reach a toxic level, 
resulting in oxidative damage and malfunctioning of the 
organ.[54]
We conducted a study on male Wistar rats to test the 
potential properties of metformin in protecting the kidney 
from gentamicin-induced acute renal failure, and to fi nd 
out by postponing the treatment with metformin in acute 
renal failure exerts similar benefits as on gentamicin 
nephrotoxicity in rats.[61] Metformin not only had preventive 
effect but also exerted ameliorative activity against 
gentamicin nephrotoxicity. Hence, it might be benefi cial in 
patients under treatment with this drug.[49]
Metformin has also shown to have benefi cial eﬀ ect on renal 
function and structure aĞ er unilateral ischemia-reperfusion 
in rats.[62] The authors in this study have concluded that 
metformin has tissue protection with the activation of 
endothelial nitric oxide synthase and AMPK.[61]
Various studies have shown that ROS overproduction might 
be the key starting events, which cause development of 
complications of diabetes.[63] However, the exact mechanisms 
that cause hyperglycemia and diabetic nephropathy are not 
elucidated.[64] It has been shown that nucleic acids can be 
aﬀ ected by oxidative stress, thereby modifying the bases 
in DNA. When DNA is damaged the aﬀ ected cells start a 
response such as cell cycle delay, DNA repair or apoptosis 
induction. ROS generation by oxidative stress causes cell 
death.[65] Apoptosis is implicated in the pathogenesis of 
diabetic nephropathy. ROS is an inducer of apoptosis in 
various cell types including podocytes.[66]
Metformin is able to restore the podocytes in diabetic rats 
and diabetes-induced podocyte loss in diabetic nephropathy 
has been attenuated to ROS.[67] Podocyte apoptosis is 
associated with increased albuminuria. Phosphorylation of 
AMPK is reduced in the kidney of diabetic rats. Therefore, 
metformin may exert some of its eﬀ ects by improving the 
renal oxidative stress.[67] These fi ndings are in agreement 
with other studies showing benefi cial antioxidant properties 
of metformin in diabetic rats.[68]
These fi ndings may encourage the clinical use of metformin 
along with nephrotoxic drugs as well as for prevention of 
diabetic nephropathy.
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Side eﬀ ects
Metformin has not signifi cant adverse eﬀ ects; however, it 
may cause a serious condition called lactic acidosis with 
the following symptoms: Dizziness, severe drowsiness, 
muscle pain, tiredness, chills, blue/cold skin, fast/diﬃ  cult 
breathing, slow/irregular heartbeat, stomach pain with 
diarrhea, nausea or vomiting.[1,41,43,69]
Lactic acidosis usually occurs due to drug overdose or in 
some contraindicated conditions. It is more likely to occur 
in patients with certain medical conditions, including a 
serious infection, liver or kidney disease, recent surgery, 
any conditions that cause a low level of oxygen in the blood 
or poor circulation (such as recent stroke, congestive heart 
failure, recent heart aĴ ack), heavy alcohol use, dehydration, 
X-ray or scanning procedures that require an injectable 
iodinated contrast drug and those older than 80 years.[1,41,43,70]
Nausea, vomiting, stomach upset, diarrhea, weakness, or a 
metallic taste in the mouth may occur.
Metformin usually does not cause hypoglycemia; however, 
low blood sugar may occur if this drug is used with other 
anti-diabetic drugs. Hypoglycemia is more likely to occur 
with heavy exercise, drinking large amounts of alcohol, or 
not consuming enough calories from food.
Symptoms of hyperglycemia include polydipsia, polyuria, 
rapid breathing, fl ushing, confusion, drowsiness, and fruity 
breath odor.[1,41,43,71,72]
Serious allergic reaction to this drug is rare; however, 
this product may contain inactive ingredients, which can 
cause allergic reactions or other problems. High fever, 
diarrhea, vomiting, diuretics or excess sweating may cause 
dehydration and increase the risk of lactic acidosis. Older 
adults may be at greater risk for side eﬀ ects such as low 
blood sugar or lactic acidosis.[1,41,43,62,71]
Gastrointestinal intolerance is one of the most frequently 
occurred and lactic acidosis is a rare, but causes serious 
adverse effects.[73,74] Incidence of myocardial infarction 
(MI) is also an important event but seen less in metformin 
compared with sulfonylurea agents.[75] Metformin induced 
lactic acidosis is a rare but important and fatal adverse event.
A population-based study demonstrated that about one-
fourth of patients prescribed metformin had contraindications 
to its use. However, contraindications rarely resulted in 
discontinuation of metformin usage.[76] These data have been 
confi rmed by several other studies in diﬀ erent countries.[77,78]
Furthermore, in a recent review article, based on 347 
observational cohort studies and prospective comparative 
trials, no evidence indicating metformin to be associated 
with increased levels of lactate or increased risk of lactic 
acidosis in comparison to other antihyperglycaemic 
drugs has been reported.[7-79] It should be noted that in 
this report, all clinical trials excluded the risk patients. 
Therefore, the scenario might be rather diﬀ erent, in real 
population.
In a study sample of 19,691 type 2 diabetes mellitus (DM), 
patients with established atherothrombosis participating in 
study, the two-year mortality rate was signifi cantly less in 
patients treated with metformin compared with the patients 
not treated with metformin.[80,81]
Therefore, it might be necessary to reconsider the list of 
contraindications in the use of metformin.
However, considering the high prevalence of stable renal 
impairment, congestive heart failure and/or coronary 
artery disease in elderly patients, the benefi t-risk balance of 
metformin treatment are of particular important and more 
valuable data especially relevant to the elderly population 
are still required. In this regard, benefi t-risk ratios are 
needed without deprivation of patients at risk.
METFORMIN DURING PREGNANCY AND LACTATION
It has been shown that pregnancy may alter the function 
of drug-metabolizing enzymes and drug transporters 
in a gestational stage. The activities of several hepatic 
cytochrome P450 enzymes such as CYP2D6 and CYP3A4 
are increased, whereas the activity of some others, such 
as CYP1A2, may be decreased. The activities of some 
renal transporters, including organic-cation transporter 
and P-glycoprotein increase during pregnancy. However, 
signifi cant gaps still exist in our understanding of the 
spectrum of drug metabolism and transport genes 
affected, gestational age-dependent changes in the 
activity of encoded drug metabolizing and transporting 
processes, and the mechanisms of pregnancy-induced 
alterations.[52,82]
The pharmacokinetics of metformin is also aﬀ ected by 
pregnancy, which is related to the changes in renal fi ltration 
and net tubular transport, which can be estimated roughly 
by the use of creatinine clearance. At the time of delivery, 
the fetus is exposed to variable concentrations of metformin 
from negligible to as high as maternal concentrations. 
However, infant exposure to metformin through the breast 
milk is low.[83]
Metformin appears to be effective and safe for the 
treatment of gestational diabetes mellitus, particularly 
for overweight or obese women. It has been suggested 
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that metformin is safe during pregnancy. However, 
as metformin crosses the placenta, its use during 
pregnancy raises concerns regarding potential adverse 
eﬀ ects on the mother and fetus. Furthermore, patients 
with multiple risk factors for insulin resistance may 
not meet their treatment goals with metformin alone 
and may require supplementary drugs such as insulin. 
However, there are potential advantages for the use of 
metformin over insulin in gestational diabetes mellitus 
with respect to maternal weight gain and neonatal 
outcomes. Furthermore, the use of metformin throughout 
pregnancy in women with polycystic ovary syndrome 
decreases the rates of early pregnancy loss and preterm 
labor; hence protecting against fetal growth restriction. 
There have been no demonstrable teratogenic eﬀ ects, 
intrauterine deaths or developmental delays with the 
use of metformin. Therefore, the evidence supports the 
eﬃ  cacy and safety of metformin during pregnancy with 
respect to immediate pregnancy outcomes. However, 
because there are no guidelines for the continuous use 
of metformin in pregnancy, the duration of treatment is 
based on clinical judgment and experience on a case-by-
case basis.[84-89] Recently, the Endocrin Society has not 
only confi rmed the use of metformin during pregnancy 
but also has recommended it as a fi rst-line treatment of 
cutaneous manifestations, for prevention of pregnancy 
complications, or for the treatment of obesity.[85,86] It should 
be noted that not all references allow the use of metformin 
in the fi rst trimester of pregnancy.[90] Therefore, it is 
suggested that metformin therapy be used for glycemic 
control only for those women with gestational diabetes 
who do not have satisfactory glycemic control despite 
medical nutrition therapy and who refuse or cannot use 
insulin or glyburide in the fi rst trimester.
CONCLUSION
Metformin is an oral anti-diabetic drug in the biguanide 
class for the treatment of type 2 diabetes mellitus, in 
particular, in overweight and obese people and those with 
normal kidney function.
Metformin has several benefits in patients with type 
2 diabetes mellitus, including decreased hyperinsulinemia, 
weight reduction, augmented fi brinolysis, improved lipid 
profi les and enhanced endothelial function.
Although the use of metformin in diabetes has its safety 
concerns, its benefi ts and the recent results indicate that 
the nephroprotective activity against nephrotoxic agents 
on metformin and its recent good safety records have led 
researchers to consider the use of this drug more and more 
in insulin resistant states even before the development of 
hyperglycemia.
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